Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines

Br J Cancer. 1994 Mar;69(3):482-6. doi: 10.1038/bjc.1994.87.


Platinum analogues are frequently used in the treatment of advanced or recurrent endometrial cancer. To study the sensitivity of endometrial cancer to cisplatin and carboplatin, we tested two long-established (RL95-2, KLE) and six new cell lines (UM-EC-1, UM-EC-2, UM-EC-3, UT-EC-2A, UT-EC-2B, UT-EC-3) using the 96-well-plate clonogenic assay. This assay has proven to be suitable for testing chemosensitivity of both adenocarcinoma and squamous cell carcinoma. The chemosensitivity was expressed as an IC50 value, the drug concentration causing 50% inhibition of clonogenic survival. IC50 values were obtained from dose-response curves after fitting the data by the linear quadratic equation, F = exp[-(alpha D + beta D2)]. The IC50 values of the two platinum derivatives varied considerably. The values for cisplatin varied between 0.022 microgram ml-1 and 0.56 microgram ml-1 and the corresponding values for carboplatin were 0.096-1.20 microgram ml-1. The range of the ratios between carboplatin IC50 and cisplatin IC50, from 1.5:1 to 4.4:1, was rather narrow. However, no constant ratio between carboplatin IC50 and cisplatin IC50 could be detected. The equivalent doses with regard to efficacy of these two platinum analogues remain to be determined.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma
  • Carboplatin / therapeutic use*
  • Cell Division / drug effects
  • Cell Line
  • Cell Survival / drug effects
  • Cisplatin / toxicity*
  • Dose-Response Relationship, Drug
  • Endometrial Neoplasms
  • Female
  • Humans
  • Kinetics
  • Tumor Cells, Cultured
  • Tumor Stem Cell Assay


  • Carboplatin
  • Cisplatin